Immediately prior to the passage of the 1962 Food and Drug Administrat
ion Amendments, there were a number of drugs recalled from markets wor
ldwide. Announcements about the dangerous side effects of these drugs
were associated with lower share prices for their manufacturers and th
e industry as a whole. We perform several analyses to sort out alterna
tive explanations for the observed declines. We find that dangerous dr
ug announcements had no effect on the sales of other drugs and did not
affect the share values of European drug makers doing little business
in the United States. We also find that share price reductions associ
ated with recalls in the 1970s and 1980s were confined to the manufact
urers of the recalled drugs. These patterns are consistent with the hy
pothesis that drug company shareholders viewed the recalls in the earl
y 1960s as signals of an increase in the cost of compliance with new (
and more stringent) drug testing requirements.